Medical Morphine Market Size, Share, Growth, Analysis, Trends, and Forescast to 2024 Hexa Research Increasing use of the drug to relieve pain in cancer, arthritis and postoperative surgeries is expected to drive medical morphine market growth over the forecast period. 22 November 2018 - The global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively. North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market. In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts. On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally. Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market
Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine. Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of Ca lifornia San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies. Hexa Research has segmented the global medical morphine market based on Route of Administration, Indication and region: Segmentation by Route of Administration, 2014-2024 (USD Million) Oral Injectables Others Segmentation by Indication, 2014-2024 (USD Million) Cancer Arthritis Others Segmentation by Region, 2014-2024 (USD Million) North America U.S. Europe Germany Asia Pacific China India Rest of the World Key players analyzed Mallinckrodt Pharmaceuticals Alcaliber S.A. Purdue Pharma L.P. Pfizer Inc. Johnson Matthey Fine Chemicals Sun Pharmaceutical Industries Ltd. Verve Health Care Ltd. Taj Pharmaceuticals Limited
NORTHEAST PHARM MANUS AKTTEVA BIOPHARMA LLP Your Catalyst to a Lucrative Business Browse Related Category Market Reports @ https://www.hexaresearch.com/researchcategory/pharmaceuticals-industry
Table of Contents of Medical Morphine Market: Your Catalyst to a Lucrative Business Chapter 1. Market Summary 1.1. Market trends & movement Chapter 2. Global Medical Morphine Market Trends: Drivers & Opportunities 2.1. Introduction 2.2. Key industry trends 2.2.1. Supplier trend 2.2.2. Buyer trend 2.2.3. Regulatory trend 2.3. Market drivers 2.4. Market restraints 2.5. Opportunity Assessment 2.6. Raw material Analysis 2.7. Value chain analysis 2.8. PESTEL Analysis 2.9. Porter's Five Forces analysis 2.10. SWOT Chapter 3. Global Medical Morphine Market Trends, By Route of Administration 3.1. Global Medical Morphine market movement, by route of administration, 2016 & 2024 3.1.1. Oral 3.1.1.1. Market estimates and forecast, 2014-2024 (USD Million) 3.1.2. Injectables 3.1.2.1. Market estimates and forecast, 2014-2024 (USD Million) 3.1.3. Others 3.1.3.1. Market estimates and forecast, 2014-2024 (USD Million) Chapter 4. Global Medical Morphine Market Trends, By Indication 4.1. Global Medical Morphine market movement, by indication, 2016 & 2024 4.1.1. Cancer 4.1.1.1. Market estimates and forecast, 2014-2024 (USD Million) 4.1.2. Arthritis 4.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.3. Others Your Catalyst to a Lucrative Business 4.1.3.1. Market estimates and forecast, 2014-2024 (USD Million) Chapter 5. Global Medical Morphine Market Trends, By Region 5.1. Global Medical Morphine market movement, by region, 2016 & 2024 5.1.1. North America 5.1.1.1. Market estimates and forecast, 2014-2024 (USD Million) 5.1.1.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 5.1.1.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 5.1.2. Europe 5.1.2.1. Market estimates and forecast, 2014-2024 (USD Million) 5.1.2.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 5.1.2.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 5.1.3. Asia-Pacific 5.1.3.1. Market estimates and forecast, 2014-2024 (USD Million) 5.1.3.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 5.1.3.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 5.1.4. Rest of the World (RoW) 5.1.4.1. Market estimates and forecast, 2014-2024 (USD Million) 5.1.4.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 5.1.4.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) Chapter 6. Key Country Markets 6.1. U.S. 6.1.1. Market estimates and forecast, 2014-2024 (USD Million) 6.1.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 6.1.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 6.2. Germany 6.2.1. Market estimates and forecast, 2014-2024 (USD Million) 6.2.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 6.2.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 6.3. China
6.3.1. Market estimates and forecast, 2014-2024 (USD Million) 6.3.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 6.3.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) 6.4. India 6.4.1. Market estimates and forecast, 2014-2024 (USD Million) 6.4.2. Market estimates and forecast, by route of administration, 2014-2024 (USD Million) 6.4.3. Market estimates and forecast, by indication, 2014-2024 (USD Million) Chapter 7. Competitive Landscape 7.1. Competitive landscape analysis, 2016 7.2. Strategic framework 7.3. Potential customer base concentration 7.4. Company market positioning 7.5. Company profiles 7.5.1. Mallinckrodt Pharmaceuticals 7.5.1.1. Company Overview 7.5.1.2. Financial Performance 7.5.1.3. Product Benchmarking 7.5.1.4. SWOT 7.5.1.5. Recent Initiatives 7.5.1.6. Future Outlook and Strategies 7.5.2. Purdue Pharma L.P. 7.5.2.1. Company Overview 7.5.2.2. Financial Performance 7.5.2.3. Product Benchmarking 7.5.2.4. SWOT 7.5.2.5. Recent Initiatives 7.5.2.6. Future Outlook and Strategies 7.5.3. Pfizer, Inc. 7.5.3.1. Company Overview 7.5.3.2. Financial Performance 7.5.3.3. Product Benchmarking 7.5.3.4. SWOT 7.5.3.5. Recent Initiatives 7.5.3.6. Future Outlook and Strategies 7.5.4. Johnson Matthey Fine Chemicals
7.5.4.1. Company Overview 7.5.4.2. Financial Performance 7.5.4.3. Product Benchmarking 7.5.4.4. SWOT 7.5.4.5. Recent Initiatives 7.5.4.6. Future Outlook and Strategies 7.5.5. Sun Pharmaceutical Industries Ltd. 7.5.5.1. Company Overview 7.5.5.2. Financial Performance 7.5.5.3. Product Benchmarking 7.5.5.4. SWOT 7.5.5.5. Recent Initiatives 7.5.5.6. Future Outlook and Strategies 7.5.6. Verve Health Care Ltd. 7.5.6.1. Company Overview 7.5.6.2. Financial Performance 7.5.6.3. Product Benchmarking 7.5.6.4. SWOT 7.5.6.5. Recent Initiatives 7.5.6.6. Future Outlook and Strategies 7.5.7. NORTHEAST PHARM 7.5.7.1. Company Overview 7.5.7.2. Financial Performance 7.5.7.3. Product Benchmarking 7.5.7.4. SWOT 7.5.7.5. Recent Initiatives 7.5.7.6. Future Outlook and Strategies 7.5.8. MANUS AKTTEVA BIOPHARMA LLP 7.5.8.1. Company Overview 7.5.8.2. Financial Performance 7.5.8.3. Product Benchmarking 7.5.8.4. SWOT 7.5.8.5. Recent Initiatives 7.5.8.6. Future Outlook and Strategies 7.5.9. Alcaliber S.A. 7.5.9.1. Company Overview
7.5.9.2. Financial Performance 7.5.9.3. Product Benchmarking 7.5.9.4. SWOT 7.5.9.5. Recent Initiatives 7.5.9.6. Future Outlook and Strategies 7.5.10. Taj Pharmaceuticals Limited 7.5.10.1. Company Overview 7.5.10.2. Financial Performance 7.5.10.3. Product Benchmarking 7.5.10.4. SWOT 7.5.10.5. Recent Initiatives 7.5.10.6. Future Outlook and Strategies Chapter 8. Methodology and Scope 8.1. Research methodology 8.2. Research Scope & Assumptions 8.3. List of data sources
About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website: https://www.hexaresearch.com